Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02276560 · ClinicalTrials.gov registry record · Phase 2
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02276560 is a Phase 2 study that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT02276560, a Phase 2 study, was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether giving cisplatin and nab-paclitaxel before surgery will reduce the presence of disease in certain areas of the lung at the time of surgery.
Interventions
- DRUG Neoadjuvant Cisplatin, nab-paclitaxel
- DRUG Adjuvant Cisplatin,nab-paclitaxel
- DRUG Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02276560
The ClinicalTrials.gov registry entry for NCT02276560 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Neoadjuvant Cisplatin, nab-paclitaxel is the first listed.
NCT02276560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02276560 about?
NCT02276560 is a clinical study titled "Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC". The purpose of this research study is to determine whether giving cisplatin and nab-paclitaxel before surgery will reduce the presence of disease in certain areas of the lung at the time of surgery.
What is the current status of trial NCT02276560?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02276560?
The interventions under investigation include: Neoadjuvant Cisplatin, nab-paclitaxel (DRUG), Adjuvant Cisplatin,nab-paclitaxel (DRUG), Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02276560?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.